Skip to main content
Erschienen in: Wiener klinische Wochenschrift 15-16/2020

11.11.2019 | short report

Neutral effect of Glioma-associated oncogene-1 expression on survival in myelofibrosis

verfasst von: Marko Lucijanic, MD PhD, Ana Livun, Katarina Marija Tupek, Tajana Stoos-Veic, Vlatko Pejsa, Zeljko Jonjic, Amina Fazlic Dzankic, Marija Ivic, Rajko Kusec

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 15-16/2020

Einloggen, um Zugang zu erhalten

Summary

This study retrospectively analyzed glioma-associated oncogene 1 (GLI‑1) mRNA expression in unfractionated bone marrow aspirates of 32 patients with myelofibrosis and 16 controls. It was found that GLI‑1 expression did not significantly differ between primary, secondary myelofibrosis and controls (median difference in threshold cycles ∆CT 7.2, 7.3 and 6.9, respectively; P = 0.864), as well as that survival curves of myelofibrosis patients with higher/lower GLI‑1 expression showed multiple overlaps and overall comparable course (P = 0.651). The results suggest that general upregulation of GLI‑1 does not seem to be a feature of the disease and are in line with modest biological and clinical effects observed with inhibitors of Hedgehog signaling pathway in patients with myelofibrosis.
Literatur
1.
Zurück zum Zitat Campbell V, Copland M. Hedgehog signaling in cancer stem cells: a focus on hematological cancers. Stem Cells Cloning. 2015;8:27–38.PubMedPubMedCentral Campbell V, Copland M. Hedgehog signaling in cancer stem cells: a focus on hematological cancers. Stem Cells Cloning. 2015;8:27–38.PubMedPubMedCentral
3.
Zurück zum Zitat Schneider RK, Mullally A, Dugourd A, et al. Gli1(+) mesenchymal stromal cells are a key driver of bone marrow fibrosis and an important cellular therapeutic target. Cell Stem Cell. 2017;20(6):785–800.e8.CrossRef Schneider RK, Mullally A, Dugourd A, et al. Gli1(+) mesenchymal stromal cells are a key driver of bone marrow fibrosis and an important cellular therapeutic target. Cell Stem Cell. 2017;20(6):785–800.e8.CrossRef
4.
Zurück zum Zitat Bose P, Alfayez M, Verstovsek S. New concepts of treatment for patients with myelofibrosis. Curr Treat Options Oncol. 2019;20(1):5.CrossRef Bose P, Alfayez M, Verstovsek S. New concepts of treatment for patients with myelofibrosis. Curr Treat Options Oncol. 2019;20(1):5.CrossRef
7.
Zurück zum Zitat Lucijanic M. Survival analysis in clinical practice: analyze your own data using an Excel workbook. Croat Med J. 2016;57(1):77–9.CrossRef Lucijanic M. Survival analysis in clinical practice: analyze your own data using an Excel workbook. Croat Med J. 2016;57(1):77–9.CrossRef
8.
Zurück zum Zitat Lucijanic M, Veletic I, Rahelic D, et al. Assessing serum albumin concentration, lymphocyte count and prognostic nutritional index might improve prognostication in patients with myelofibrosis. Wien Klin Wochenschr. 2018;130(3–4):126–33.CrossRef Lucijanic M, Veletic I, Rahelic D, et al. Assessing serum albumin concentration, lymphocyte count and prognostic nutritional index might improve prognostication in patients with myelofibrosis. Wien Klin Wochenschr. 2018;130(3–4):126–33.CrossRef
Metadaten
Titel
Neutral effect of Glioma-associated oncogene-1 expression on survival in myelofibrosis
verfasst von
Marko Lucijanic, MD PhD
Ana Livun
Katarina Marija Tupek
Tajana Stoos-Veic
Vlatko Pejsa
Zeljko Jonjic
Amina Fazlic Dzankic
Marija Ivic
Rajko Kusec
Publikationsdatum
11.11.2019
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 15-16/2020
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-019-01572-1

Weitere Artikel der Ausgabe 15-16/2020

Wiener klinische Wochenschrift 15-16/2020 Zur Ausgabe